CRF Announces the 2023 Pulse-Setter Award Winners

The Cardiovascular Research Foundation (CRF) is proud to announce the winners of the 2023 Pulse-Setter Awards. The awardees will be honored at The Annual Pulse of the City Gala, CRF’s signature fundraising event, on December 8, 2023, at The Plaza in New York City. The Pulse-Setter Awards shine a spotlight on extraordinary individuals and initiatives whose dedication to innovation is driving positive change in medicine and health care.

Mount Sinai Announces Partnership With the Chiba Institute of Technology in Japan Focusing on Artificial Intelligence to Transform Cardiovascular Research

Agreement aims to help make clinical trials more efficient and lead to faster advances in patient care

Mount Sinai Announces Partnership With the Brazilian Clinical Research Institute to Advance Cardiovascular Disease Research and Medical Education

Agreement aims to improve patient care and outcomes on a global scale

Redo Transcatheter Aortic Valve Replacement Proven Effective, Safe

Cedars-Sinai investigators are leaders in the innovation and use of transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. They now show that redo TAVR procedures are both safe and effective when compared with situations in which patients with similar risk profiles undergo the same procedure for the first time.

First Dedicated Heart and Vascular Hospital in Waxahachie Opening Soon

Baylor Scott & White Heart and Vascular Hospital – Waxahachie*, an expansion of the nationally recognized Baylor Scott & White Heart and Vascular Hospital – Dallas*, is now complete.

TCT 2023 Program Guide Now Available

The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 Program Guide is now available. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT 2023 will take place October 23-26 in San Francisco, California, at the Moscone Center and will celebrate 35 years of leading the field.

Study: Transcatheter Mitral Valve Repair Safe, Successful

Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral valves revealed the minimally invasive procedure to be safe and effective in nearly 90% of patients, according to Cedars-Sinai physician-scientists.

Coronary Bioresorbable Scaffolds Nearly as Safe and Effective as Conventional Metal Stents for Heart Disease Patients

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).

TVT 2023 Late-Breaking Science Announced

The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 15 Late-Breaking Clinical Science studies. An annual meeting featuring cutting-edge research and techniques for structural heart interventions, TVT will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.

TVT 2023 Program Guide Available

The program guide for TVT 2023: The Structural Heart Summit is available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.

TCT 2023 Career Achievement Award to be Presented to Stuart J. Pocock, PhD

The TCT 2023 Career Achievement Award will be presented to Stuart J. Pocock, PhD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 23-26, 2023, in San Francisco at the Moscone Center. The award is given each year to an outstanding individual who has made significant contributions to the field of interventional cardiology and transformed patient care through their career endeavors, research pursuits, and mentorship.

Media Registration for TCT 2023 Now Open

Media registration is now open for TCT 2023 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT, which will be held October 23-26, 2023 in San Francisco, California at the Moscone Center, will be celebrating 35 years of leading the field.

TCT 2023 Master Operator Award to Be Presented to William L. Lombardi, MD

The TCT Geoffrey O. Hartzler Master Operator Award will be presented to William L. Lombardi, MD during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 23-26, 2023, in San Francisco at the Moscone Center. The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and leadership.

CTO Plus 2023 Will Feature Latest Research and Techniques for Chronic Total Occlusions and Complex PCI

CTO Plus 2023 will feature the latest research and techniques for chronic total occlusions (CTO) and complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation (CRF), will take place February 23-24 at the New York Marriott Marquis in New York, NY.

Puzzle Medical Devices Inc. Wins TCT 2022 Shark Tank Innovation Competition

The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine, September 16-19 in Boston. The winner was also presented with the Jon DeHaan Foundation Award for Innovation in Cardiology.

Distinguished Clinical Researcher to Lead UCSF Interventional Cardiology Program

UCSF Health’s Heart and Vascular Center is welcoming Sammy Elmariah, MD, MPH, FACC, FAHA, FSCAI, as chief of its division of Interventional Cardiology and medical director of the division’s cardiac catheterization lab. Elmariah is a recognized expert in structural heart disease interventions and catheter-based valve therapies.

Novel TEER Repair Device Meets Primary Endpoint in Treating Degenerative Mitral Regurgitation in Patients Not Eligible for Surgery

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery.

Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

STS/ACC TVT Registry Analysis Assesses Use of Transcatheter Edge-to-Edge Repair in Severe Mitral Regurgitation and Cardiogenic Shock

An analysis from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry found that most patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) in the United States achieved successful MR reduction, and that successful repair was associated with lower mortality and heart failure (HF) hospitalizations at one year post-procedure compared with unsuccessful repair.

CRF and Fogarty Innovation Announce Agenda For TCT MedTech Innovation Forum

The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum. The summit will be held on the first day of TCT, the annual scientific symposium of CRF, on Friday, September 16. TCT will take place September 16-19, 2022, in Boston, Massachusetts, at the Boston Convention and Exhibition Center.

New educational alliance between the American Heart Association and the Cardiovascular Research Foundation announced

Two leaders in cardiovascular disease science, research and education, the American Heart Association (Association) and the Cardiovascular Research Foundation (CRF), are joining forces to strengthen and expand educational opportunities focused on advancing the latest research in cardiovascular disease and interventional therapies. The new alliance to produce joint education programs begins immediately with the organizations’ annual scientific meetings this fall. The Association will present educational programming from its annual Scientific Sessions at TCT, and CRF will deliver educational programming from its annual scientific symposium Transcatheter Cardiovascular Therapeutics (TCT) at the Association’s Scientific Sessions, beginning with TCT 2022, September 16-19 in Boston, and the Association’s Scientific Sessions 2022, November 5-7 in Chicago, respectively.

Fostering Innovation in Congenital Interventional Cardiology

Children’s Hospital Los Angeles is evaluating several novel devices for congenital heart disease—and recently performed the world’s first implant of a novel stent for babies. Since joining Children’s Hospital Los Angeles in August as the Director of Congenital Interventional Catheterization, Darren Berman, MD, has been expanding the scope of the Cardiac Catheterization Lab to include many of the newest catheter-based treatments for children and young adults with congenital heart disease.

Late-Breaking Science Announced for TVT 2022

The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. An annual meeting covering cutting-edge research and techniques for structural heart interventions, TVT will take place June 8-10, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.

TVT 2022 Program Now Available

The program for TVT 2022: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 8-10, 2022 at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.

Trial Compares Two Devices Used For Percutaneous Left Atrial Appendage Closure

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days but through different mechanism. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days.

Randomized Study Examines Outcomes of Plug-based and Suture-based Vascular Closure Following TAVR Procedures

Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis but a higher rate of access-site or access-related vascular complications.

Transcatheter Aortic Valve Replacement is Cost Effective Compared With Surgical Replacement for Low-Risk Patients

An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.

Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents

Results from SUGAR, a randomized, controlled, multicenter trial conducted exclusively in patients with diabetes mellitus (DM) and with minimum exclusion criteria, found that amphilimus-eluting stents (AES) were superior to zotarolimus-eluting stents (ZES) with regard to target lesion and target vessel failure composite outcomes at one year.

Study Finds That PCI Guided by FFR Did Not Meet Noninferiority for One-Year Outcomes Compared to Bypass Surgery

The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 trial found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease. Patients with a low SYNTAX score (which measures the complexity of coronary artery disease) had less incidence of adverse events compared to those with intermediate or high SYNTAX scores, and in this cohort of patients PCI performed more favorably.

Study Examines Combined Effects of Medical Titration and Renal Denervation Treatment–Resistant Hypertension

Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.

Intermediate-Risk Patients Have Similar Five-Year Outcomes With Transcatheter Or Surgical Aortic Valve Replacement

New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.

New Treatment Approach for Advanced Coronary Artery Disease Leads to Improved Outcomes

Study outlines better way to identify where stents are necessary

CRF Announces Free Online Access to TCT 2021

The Cardiovascular Research Foundation (CRF) is pleased to announce that the digital component of TCT 2021 will now be free for the entire interventional community. After careful consideration and achieving a critical level of support, CRF’s leadership has agreed to fully support this initiative. Complimentary online registration will include access to all content via livestream during the meeting and on-demand access for one year.

CRF Announces TCT 2021 Late-Breaking Trials and Science

The Cardiovascular Research Foundation (CRF) has announced 22 late-breaking trial and science presentations that will be reported at TCT 2021. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place November 4-6, 2021 in Orlando, Florida at the Orange County Convention Center and simultaneously broadcast live.

Late-Breaking Science Announced for TVT 2021

The Cardiovascular Research Foundation (CRF) announced that TVT 2021 will feature 12 studies as Late-Breaking Clinical Science. An annual meeting from CRF, TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.

TVT 2021 Program Now Available

The program for TVT 2021: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.

Jersey Shore University Medical Center Cardiac Team Performs Rare, Lifesaving Combined Procedures

Experts from Hackensack Meridian Jersey Shore University Medical Center’s Structural Heart Disease Program recently performed, to the program’s knowledge, New Jersey’s first transcatheter double heart valve replacement, combined with a procedure to improve blood flow in the heart. The three treatments were completed together during one visit to the academic medical center’s advanced hybrid operating room, to ensure the patient’s safety.